The Use of Convalescent Plasma to Treat Emerging Infectious Diseases: Focus on Ebola Virus Disease

Overview

Journal Curr Opin Hematol

Specialty Hematology

Date 2015 Oct 13

PMID 26457963

Citations 28

Authors

Anne M Winkler

Scott A Koepsell

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The purpose of this review is to discuss the use of convalescent plasma for the treatment of emerging infectious diseases, focusing on the recent use for the treatment of Ebola virus disease (EVD).

Recent Findings: Ebola convalescent plasma has been used as a therapy for treatment of EVD during the 2014 West Africa epidemic. Several cases from the United States and Europe have been recently published, in addition to multiple ongoing clinical trials in the United States and West Africa. Even more recently, convalescent plasma has been used for treatment of individuals with Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

Summary: Although the first reports of successful treatment with passive immune therapy date back to the early 1900s, convalescent plasma has materialized as a possible therapy for patients who develop infection from one of the emerging infectious diseases such as EVD or MERS-CoV, although the efficacy of such therapy has yet to be proven in clinical trials.

Citing Articles

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved.

Suzuki T, Asai Y, Takahashi K, Sanada M, Shimanishi Y, Terada M Heliyon. 2023; 9(10):e20568.

PMID: 37842585 PMC: 10568336. DOI: 10.1016/j.heliyon.2023.e20568.

Hyperimmune Globulins for the Management of Infectious Diseases.

Pati I, Cruciani M, Candura F, Massari M, Piccinini V, Masiello F Viruses. 2023; 15(7).

PMID: 37515229 PMC: 10385259. DOI: 10.3390/v15071543.

Convalescent Plasma in COVID-19.

Banwait R, Salabei J, Fishman T, Iyer U HCA Healthc J Med. 2023; 1(3):139-146.

PMID: 37424714 PMC: 10324704. DOI: 10.36518/2689-0216.1097.

Hemorrhagic fever viruses: Pathogenesis, therapeutics, and emerging and re-emerging potential.

Florez-Alvarez L, de Souza E, Botosso V, de Oliveira D, Ho P, Taborda C Front Microbiol. 2022; 13:1040093.

PMID: 36386719 PMC: 9640979. DOI: 10.3389/fmicb.2022.1040093.

Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.

Saied A, Nascimento M, do Nascimento Rangel A, Skowron K, Grudlewska-Buda K, Dhama K J Med Virol. 2022; 94(10):4599-4610.

PMID: 35655326 PMC: 9347534. DOI: 10.1002/jmv.27907.